Excipient |
Drug(s) |
Application |
Ref. |
PA |
CPT |
In-vitro and In-vivo on breast cancer cells |
[34] |
PCL |
CPT |
In vitro on C2C12 cancer cells |
[35] |
PEG |
CPT |
In-vitro and In-vivo on breast and ovarian cancer cells |
[36] |
DNA |
CPT |
In-vitro on A549 cancer cells |
[37] |
PLGA |
CUR |
In-vitro on carcinoma cancer cells |
[38] |
CS |
CUR |
In-vitro on MCF-7, HEP G2 and L929 cancer cells |
[39] |
CS |
CUR |
In-vitro on breast cancer cells |
[40] |
PLGA-PEG |
CUR/CH |
In-vitro and In-vivo on breast cancer cells |
[17] |
PLGA-PCL |
QUE |
In-vitro on Hepatocellular carcinoma (HepG2) cancer cells |
[41] |
PCL/PEO/PLA/PLGA |
QUE |
In-vitro on breast cancer cells |
[42] |
SoA/CS |
QUE |
In-vitro on colon cancer cells |
[43] |
CA/PEG |
QUE |
In-vtiro on HeLa tumor and SH-4 skin cancer cells (melanoma) |
[44] |
PCL |
EO |
In-vitro on MCF-7 cancer cells |
[45] |